# Artivion, Inc.

**AORT**

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000784199

# B/C

**on the B/C boundary of 370 graded peers in healthcare**

rank 144 of 370; percentile 38.8; sampling error 2.5 points; lower is stronger




**B/C, the elk**



## Scoreboard

| | | |
|---|---|---|
| **Profitability** | C | percentile 46.9 |
| **Solvency** | C | percentile 47.7 |
| **Growth and financing** | B/C | percentile 38.9 |
| **Reliability** | 0.91 AUC | filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year | Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets | total assets $884.8M |
| **Standard universe** | inside | revenue above $1M and assets above $10M |
| **Warnings** | none triggered | not computable: distress |
| **Inputs computable** | 11 of 14 | |
| **Graded from** | filings received through Feb 18, 2026 | 244 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026 |
| **Last close** | $22.25 | 2026-10-19; market equity $1.1B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 18, 2026*

Artivion, Inc. ("Artivion," the "Company," "we," or "us"), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products ("On-X" products), surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 46.9** | | | | | | |
| Gross profitability | 32.1% | 32.3% | | 46.2 | 371 | 2025-12-31 |
| Return on invested capital | 3.9% | 9.3% | | 65.8 | 74 | 2025-12-31 |
| Accruals ratio | (3.6%) | (6.6%) | | 68.6 | 812 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Gross margin stability, five years | 0.7 pts | 2.8 pts | 7.1 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 47.7** | | | | | |
| Twelve-month failure probability | not computable | 0.06% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | 3.05 | (0.30) | 25.1 | 757 | 2025-12-31 |
| Net debt to EBITDA | 2.67x | 1.82x | 66.2 | 75 | 2025-12-31 |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 3.53x | 2.96x | 51.7 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 38.9** | | | | | |
| Revenue growth, three-year compound | 12.0% | 10.1% | 45.8 | 414 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | 223.5% | 37.1% | 13.6 | 104 | 2025-12-31 |
| Asset growth, three years | 5.1% | 2.1% | 40.6 | 705 | 2025-12-31 |
| Net share issuance, one year | 13.9% | 2.5% | 55.8 | 634 | 2026-02-13 |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 139 | LifeMD, Inc. (LFMD) | 37.5 | B/C | late filer |
| 140 | LifeMD, Inc. (LFMDP) | 37.5 | B/C | late filer |
| 141 | Collegium Pharmaceutical, Inc. (COLL) | 37.9 | B/C | fortress balance sheet |
| 142 | Sunshine Biopharma Inc. (SBFM) | 38.3 | B/C | late filer |
| 143 | Sunshine Biopharma Inc. (SBFMW) | 38.3 | B/C | late filer |
| 144 | Artivion, Inc. (AORT) | 38.8 | B/C | |
| 145 | Lakeland Industries Inc. (LAKE) | 39.0 | B/C | late filer, fortress balance sheet |
| 146 | LifeStance Health Group, Inc. (LFST) | 39.3 | B/C | |
| 147 | UroGen Pharma Ltd. (URGN) | 39.6 | B/C | short runway |
| 148 | National Healthcare Corp. (NHC) | 39.8 | B/C | fortress balance sheet |
| 149 | Biolife Solutions Inc. (BLFS) | 40.1 | B/C | fortress balance sheet |

## What the price implies

*at the 2026-10-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (36.3%) | 8.0% | 19 |
| Distance from 52-week high | (53.2%) | (31.9%) | 25 |
| EBIT to enterprise value | 2.5% | (1.6%) | 63 |
| Free cash flow yield | 0.08% | (1.0%) | 55 |
| Book value to price | 0.41 | 0.28 | 62 |
| Sales to price | 0.41 | 0.31 | 59 |
| Composite equity issuance, five years | 22.4% | 20.3% | 51 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Relative strength against the sector, log excess return | (0.66) | (0.13) | 19 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 7 of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $77.3M |
| Operating cash flow, four quarters | $41.7M |
| Months of runway | not finite |
| Days since last periodic filing | 74 (10-Q received Aug 7, 2026) |
| Median daily dollar volume, 63 sessions | $14.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $284.2M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 2 | assets | us-gaap:Assets | $884.8M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $33.7M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $14.8M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $5.0M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 6 | total debt | us-gaap:LongTermDebt | $215.1M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 7 | book equity | us-gaap:StockholdersEquity | $448.2M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $64.9M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 9 | total debt | us-gaap:LongTermDebt | $314.3M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 10 | book equity | us-gaap:StockholdersEquity | $276.2M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $53.5M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 12 | net income | us-gaap:NetIncomeLoss | $9.8M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $39.9M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 14 | assets | us-gaap:Assets | $789.1M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $441.3M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 16 | gross profit | us-gaap:GrossProfit | $248.8M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $388.5M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 18 | gross profit | us-gaap:GrossProfit | $229.2M | 2023-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $354.0M | 2023-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 20 | gross profit | us-gaap:GrossProfit | $202.5M | 2022-12-31 | 2025-02-28 | 10-K | 25-000029 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $313.8M | 2022-12-31 | 2025-02-28 | 10-K | 25-000029 |
| 22 | gross profit | us-gaap:GrossProfit | $197.5M | 2021-12-31 | 2024-02-23 | 10-K | 24-000033 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $298.8M | 2021-12-31 | 2024-02-23 | 10-K | 24-000033 |
| 24 | current assets | us-gaap:AssetsCurrent | $358.1M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $101.6M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$51.5M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 27 | liabilities | us-gaap:Liabilities | $436.6M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $22.5M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 29 | operating income | us-gaap:OperatingIncomeLoss | $5.7M | 2023-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 30 | interest expense | us-gaap:InterestExpense | $25.3M | 2023-12-31 | 2024-02-23 | 10-K | 24-000033 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $39.0M | 2025-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $22.2M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $11.2M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $18.8M | 2023-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $9.8M | 2023-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.2M | 2022-12-31 | 2025-02-28 | 10-K | 25-000029 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.7M | 2022-12-31 | 2025-02-28 | 10-K | 25-000029 |
| 38 | current assets | us-gaap:AssetsCurrent | $290.1M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 39 | current liabilities | us-gaap:LiabilitiesCurrent | $66.8M | 2024-12-31 | 2026-02-18 | 10-K | 26-009046 |
| 40 | assets | us-gaap:Assets | $792.4M | 2023-12-31 | 2025-02-28 | 10-K | 25-000029 |
| 41 | assets | us-gaap:Assets | $762.8M | 2022-12-31 | 2024-02-23 | 10-K | 24-000033 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 47,883,897 | 2026-02-13 | 2026-02-18 | 10-K | 26-009046 |
| 43 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 42,047,888 | 2025-02-21 | 2025-02-28 | 10-K | 25-000029 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.